Eli Lilly’s stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is poised for a breakout by FY2025.
Eli Lilly’s Breakout Is Nearly Here: Performance Metrics/Bullish Support Remain Robust
view original post